EP 3952840 A1 20220216 - PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING MENTAL, BEHAVIORAL, COGNITIVE DISORDERS
Title (en)
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING MENTAL, BEHAVIORAL, COGNITIVE DISORDERS
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON MENTALEN, VERHALTENSBEZOGEN, KOGNITIVEN STÖRUNGEN
Title (fr)
COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT DE TROUBLES MENTAUX, COMPORTEMENTAUX ET COGNITIFS
Publication
Application
Priority
US 2019027293 W 20190412
Abstract (en)
[origin: WO2020209872A1] A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.
IPC 8 full level
A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/13 (2006.01); A61K 31/495 (2006.01); A61K 31/55 (2006.01); A61K 47/00 (2006.01)
CPC (source: EP)
A61K 31/13 (2013.01); A61K 31/55 (2013.01); A61P 25/28 (2017.12)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020209872 A1 20201015; AU 2019445048 A1 20211202; CA 3136633 A1 20201015; CN 113939276 A 20220114; EP 3952840 A1 20220216; EP 3952840 A4 20221123; JP 2022535644 A 20220810; JP 7365426 B2 20231019
DOCDB simple family (application)
US 2019027293 W 20190412; AU 2019445048 A 20190412; CA 3136633 A 20190412; CN 201980095322 A 20190412; EP 19924315 A 20190412; JP 2021556914 A 20190412